IL162529A0 - Corticotropin releasing factor 2 receptor agonists - Google Patents

Corticotropin releasing factor 2 receptor agonists

Info

Publication number
IL162529A0
IL162529A0 IL15252903A IL15252903A IL162529A0 IL 162529 A0 IL162529 A0 IL 162529A0 IL 15252903 A IL15252903 A IL 15252903A IL 15252903 A IL15252903 A IL 15252903A IL 162529 A0 IL162529 A0 IL 162529A0
Authority
IL
Israel
Prior art keywords
receptor agonists
releasing factor
corticotropin releasing
corticotropin
factor
Prior art date
Application number
IL15252903A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL162529A0 publication Critical patent/IL162529A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15252903A 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists IL162529A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19
PCT/US2003/001451 WO2003062268A2 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists

Publications (1)

Publication Number Publication Date
IL162529A0 true IL162529A0 (en) 2005-11-20

Family

ID=27617822

Family Applications (5)

Application Number Title Priority Date Filing Date
IL16253003A IL162530A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists
IL16243103A IL162431A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
IL15252903A IL162529A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
IL196384A IL196384A0 (en) 2002-01-16 2009-01-07 Corticotropin releasing factor 2 receptor agonists
IL197774A IL197774A0 (en) 2002-01-16 2009-03-24 Corticotropin releasing factor 2 receptor agonists

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL16253003A IL162530A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists
IL16243103A IL162431A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL196384A IL196384A0 (en) 2002-01-16 2009-01-07 Corticotropin releasing factor 2 receptor agonists
IL197774A IL197774A0 (en) 2002-01-16 2009-03-24 Corticotropin releasing factor 2 receptor agonists

Country Status (30)

Country Link
US (7) US6936585B2 (xx)
EP (4) EP1465922B1 (xx)
JP (3) JP4508648B2 (xx)
KR (3) KR100735586B1 (xx)
CN (3) CN100475844C (xx)
AR (3) AR038144A1 (xx)
AT (4) ATE398632T1 (xx)
AU (2) AU2003205197B2 (xx)
BR (3) BR0306838A (xx)
CA (3) CA2470731C (xx)
CY (1) CY1106133T1 (xx)
DE (4) DE60307044T2 (xx)
DK (2) DK1465923T3 (xx)
ES (4) ES2269976T3 (xx)
HK (1) HK1078095A1 (xx)
IL (5) IL162530A0 (xx)
MA (3) MA27590A1 (xx)
MX (3) MXPA04006883A (xx)
MY (1) MY140306A (xx)
NO (3) NO20043371L (xx)
NZ (3) NZ533598A (xx)
PE (3) PE20030849A1 (xx)
PL (3) PL373529A1 (xx)
PT (2) PT1465921E (xx)
RU (1) RU2294333C2 (xx)
SA (3) SA03230564B1 (xx)
SI (1) SI1465921T1 (xx)
TW (3) TW200302278A (xx)
WO (3) WO2003062277A1 (xx)
ZA (1) ZA200404995B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049009A1 (en) * 2000-09-22 2004-03-11 Klaus Eckart Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
US20100034822A1 (en) * 2005-03-30 2010-02-11 Vega Masignani Haemophilus Influenzae Type B
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2009033692A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
KR20100059862A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
MX2011004718A (es) * 2008-11-04 2011-07-28 Janssen Pharmaceutica Nv Péptidos agonistas de crhr2 y usos de éstos.
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
BR112012010661A2 (pt) * 2009-11-04 2016-11-22 Janssen Pharmaceutica Nv método para tratar insuficiência cardíaca com peptídeos semelhantes à estressecopina
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
WO2013123094A2 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018075973A2 (en) * 2016-10-20 2018-04-26 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
CA2418144C (en) 2000-08-04 2013-06-18 Research Development Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
KR20040082392A (ko) 2004-09-24
DE60318547T2 (de) 2008-12-24
ATE362488T1 (de) 2007-06-15
DE60321730D1 (de) 2008-07-31
SA03230565B1 (ar) 2006-10-31
EP1465923A1 (en) 2004-10-13
MA27591A1 (fr) 2005-11-01
US20030148956A1 (en) 2003-08-07
PL371364A1 (en) 2005-06-13
DK1465921T3 (da) 2006-11-27
SI1465921T1 (sl) 2006-10-31
SA03230564A (ar) 2005-12-03
CA2470656A1 (en) 2003-07-31
DE60307044D1 (de) 2006-09-07
US20060025339A1 (en) 2006-02-02
NZ533599A (en) 2007-03-30
TW200302277A (en) 2003-08-01
WO2003062268A3 (en) 2003-11-27
EP1724283A3 (en) 2007-04-11
DE60313845T2 (de) 2008-01-31
CN1617885A (zh) 2005-05-18
PT1465921E (pt) 2006-12-29
ES2287484T3 (es) 2007-12-16
RU2004124847A (ru) 2005-04-20
AU2003237419B2 (en) 2006-04-13
KR100758857B1 (ko) 2007-09-14
ES2309909T3 (es) 2008-12-16
DE60318547D1 (de) 2008-02-21
ATE334147T1 (de) 2006-08-15
US7608701B2 (en) 2009-10-27
US20030148957A1 (en) 2003-08-07
MA27592A1 (fr) 2005-11-01
MXPA04006883A (es) 2004-12-06
US7462597B2 (en) 2008-12-09
CY1106133T1 (el) 2011-06-08
KR100758858B1 (ko) 2007-09-14
JP4489434B2 (ja) 2010-06-23
TW200302276A (en) 2003-08-01
EP1465921B1 (en) 2006-07-26
ES2299701T3 (es) 2008-06-01
BR0306826A (pt) 2005-09-06
CA2470656C (en) 2011-06-28
PT1465923E (pt) 2007-08-06
SA03230564B1 (ar) 2006-10-31
EP1465922A2 (en) 2004-10-13
MXPA04006885A (es) 2004-12-06
WO2003062269A2 (en) 2003-07-31
JP2005522191A (ja) 2005-07-28
JP4508648B2 (ja) 2010-07-21
US20080004435A1 (en) 2008-01-03
KR100735586B1 (ko) 2007-07-04
US7192923B2 (en) 2007-03-20
CA2470743A1 (en) 2003-07-31
US7632933B2 (en) 2009-12-15
US20030148958A1 (en) 2003-08-07
US20090124793A1 (en) 2009-05-14
EP1465923B1 (en) 2007-05-16
IL197774A0 (en) 2009-12-24
PE20030747A1 (es) 2003-10-23
EP1724283B1 (en) 2008-06-18
NZ533598A (en) 2007-03-30
RU2294333C2 (ru) 2007-02-27
US7897731B2 (en) 2011-03-01
ATE398632T1 (de) 2008-07-15
AR038143A1 (es) 2004-12-29
NO20043396L (no) 2004-10-06
WO2003062277A1 (en) 2003-07-31
JP2005521387A (ja) 2005-07-21
AU2003205197B2 (en) 2006-03-02
KR20040082389A (ko) 2004-09-24
SA03230565A (ar) 2005-12-03
CN1617887A (zh) 2005-05-18
CA2470731A1 (en) 2003-07-31
CN100391972C (zh) 2008-06-04
PE20030974A1 (es) 2003-12-26
US20100197579A1 (en) 2010-08-05
JP2005525101A (ja) 2005-08-25
WO2003062268A2 (en) 2003-07-31
CA2470731C (en) 2011-06-21
IL162530A0 (en) 2005-11-20
KR20040082390A (ko) 2004-09-24
AR038142A1 (es) 2004-12-29
NO20043366L (no) 2004-10-06
NZ533600A (en) 2007-02-23
TW200302278A (en) 2003-08-01
HK1078095A1 (en) 2006-03-03
IL196384A0 (en) 2011-07-31
MXPA04006884A (es) 2004-12-06
JP4508649B2 (ja) 2010-07-21
ES2269976T3 (es) 2007-04-01
ZA200404995B (en) 2005-06-29
MA27590A1 (fr) 2005-11-01
BR0306878A (pt) 2004-10-26
PL373529A1 (en) 2005-09-05
BR0306838A (pt) 2005-04-05
DE60313845D1 (de) 2007-06-28
DK1465923T3 (da) 2007-07-02
DE60307044T2 (de) 2007-02-15
MY140306A (en) 2009-12-31
EP1465921A2 (en) 2004-10-13
WO2003062269A3 (en) 2003-11-06
CN100475844C (zh) 2009-04-08
NO20043371L (no) 2004-10-06
IL162431A0 (en) 2005-11-20
EP1724283A2 (en) 2006-11-22
AR038144A1 (es) 2004-12-29
PE20030849A1 (es) 2003-12-01
ATE383372T1 (de) 2008-01-15
CA2470743C (en) 2011-12-13
TWI300442B (en) 2008-09-01
US6936585B2 (en) 2005-08-30
EP1465922B1 (en) 2008-01-09
PL373139A1 (en) 2005-08-22
CN1617886A (zh) 2005-05-18
US7192924B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
IL196384A0 (en) Corticotropin releasing factor 2 receptor agonists
EP1482895A4 (en) AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
IL150632A0 (en) Corticotropin releasing factor antagonists
EP1482896A4 (en) AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
EP1559422A4 (en) CONTROLLER OF RECEIVER FUNCTION
HUP0401437A3 (en) Adenosine a3 receptor agonists
AU6497701A (en) Melanocortin receptor agonists
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
GB0226227D0 (en) Receptors
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
SI1465923T1 (sl) Agonisti receptorja 2 faktorja sproščanja kortikotropina
GB0215389D0 (en) Receptor
AU2003300867A8 (en) Uses of the snorf207 receptor
GB0223399D0 (en) Receptors
AU2002302807A1 (en) Corticotropin releasing factor antagonists
GB0201849D0 (en) A�- adenosine receptor agonists
GB0201919D0 (en) A�-Adenosine receptor agonists
SI1558615T1 (sl) Purinske spojine in uporaba le-teh kot ligandov kanabinoidnega receptorja
GB0408398D0 (en) Leptin receptor agonists (3)
GB0408454D0 (en) Leptin receptor agonists (1)
GB0302925D0 (en) 4P re use 001
AU2003297644A8 (en) Uses of the snorf55 receptor